Dyslipidemia Management in Chinese Post Stroke Patients

AstraZeneca

Status: Completed

Conditions: Brain Ischemia,Stoke

Study type: Observational

Funder types: Industry

Identifiers

NCT01897883

NIS-NCN-XXX-2013/1

Details and patient eligibility

About

The purpose of this study is to provide current and reliable data of dyslipidimia management together with control situation of blood pressure and glucose for post-stroke patients within 6-12 months from attack, and also the association between patient characteristics and control rate of lipids in this population.

It is an non-interventional study, no study specified treatment is required.Approximately 5000 post ischemic stroke patients within 6-12 months from attack will enter into the study. Fifty centres from different regions of China will participate in this study.

Full description

This is a multicentre, cross-sectional, observational study, aiming to investigate the prevalence and control situation of dyslipidimia in China post ischemic stroke patients within 6-12 months from attack. Patients will be screened consecutively, eligible subjects will be interviewed by investigator and finish a questionire during the visit. Investigator will collect relevant medical history, physical exam results and lab test results including blood lipid (i.e. Triglyceride, Total Cholesterol, LDL-C, HDL-C) and glucose(HbA1c if available).Approximately 5000 post ischemic stroke patients within 6-12 months from attack will enter into the study. Fifty centres from different regions of China will participate in this study.

Enrollment: 5,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female with age ≥ 18 years
2. Post ischemic stroke patients within 6-12 months from attack
3. written informed consent is provided to participant in the study

Exclusion criteria

1. Significant medical or psychological condition that make patients can not finish the questionnaire independently or with the aids of his/her legal representatives
2. The patient is or will be in another clinical study
3. Previous enrolment in the present study

Trial design

5,000 participants in 1 patient group

One Group

Description:

Full Analysis Set (FAS) will be the primary analysis set. All post ischemic stroke patients within 6-12 months from attack (i.e., with inclusion criterion No.2 fulfilled) except the screening failure patients, i.e., those who withdraw from the study once the informed consent is given, will be included in the FAS.